Humana’s $2.8 bn BlackRock deal follows Medicare Advantage ratings recovery
Humana (HUM) agreed to a $2.8 bn deal with BlackRock, restructuring ownership of 150 CenterWell clinics. BlackRock acquires WCAS's majority stake, with Humana retaining minority ownership. The deal reduces Humana's balance sheet obligations. Humana's Medicare Advantage star ratings improved, potentially increasing 2028 bonus payments to $4.8 bn, per Evercore ISI. S&P affirmed Humana's BBB rating but maintained a negative outlook.
How this was made
The 30-second read
Why it matters
The partnership reduces debt‑like obligations and may improve credit outlook, supporting a near‑term price rally.
Market read
A large‑scale capital restructuring for Humana with a $2.8 bn valuation, likely to move its stock.
What to watch
Regulatory approvals and the future performance of CenterWell clinics remain uncertain, potentially limiting upside.
Background
Humana is recovering its Medicare Advantage star ratings, positioning for higher federal quality bonuses.
Ticker impact
Humana announced a $2.8 bn BlackRock joint‑venture deal that restructures ownership of 150 CenterWell clinics, reducing balance‑sheet liabilities.
upside pressure as investors price in reduced liabilities and longer‑term capital flexibility
The transaction removes a put option and creates a derivative liability measured at fair value, but overall balance‑sheet risk is cut.
BlackRock, via HPS Investment Partners, will acquire WCAS’s majority stake in the CenterWell joint venture, expanding its health‑care private‑equity exposure.
neutral to modest upside as the deal is a strategic expansion rather than a earnings driver
The investment is sizable but does not immediately affect BlackRock’s earnings; market impact will be limited.
Market effects
Highlights growing private‑equity involvement in Medicare Advantage, may spur other insurers to seek similar JV structures.
U.S. health‑care sector could see modest re‑rating as balance‑sheet risk improves for Humana.
Limited to U.S. health‑care investors; no broader macro effect.
Counterpoint
The deal could dilute Humana's earnings per share and introduce new derivative liabilities, weighing on the stock.
Key entities
- companyHumana
U.S. health insurer (NYSE:HUM) entering a joint venture with BlackRock.
- companyBlackRock
Asset manager (NYSE:BLK) acquiring a majority stake in the CenterWell JV.
